PRTA Stock Analysis: Buy, Sell, or Hold?
PRTA - Prothena Corporation plc Ordinary Shares
$8.25
-0.01 (-0.12%)
▼
5d:
-6.14%
30d:
-14.06%
90d:
-10.42%
HOLD
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Get Alerted When PRTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRTA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PRTA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: PRTA is currently trading at $8.25, which is considered oversold relative to its 30-day fair value range of $8.70 to $10.09. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.3) compared to its historical average (18.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRTA is in a strong uptrend. Immediate support is located at $7.73, while resistance sits at $10.07.
Market Sentiment: PRTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.40 (+159.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRTA is in a strong uptrend. Immediate support is located at $7.73, while resistance sits at $10.07.
Market Sentiment: PRTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.40 (+159.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.70 -
$10.09
Company Quality Score
53/100
(HOLD)
Options IV Signal
23th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
69.2%
Protect Your Profits
Holding PRTA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 23th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 159.4% below Wall St target ($21.40)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$8.70 -
$10.09
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.95
(11.5%)
Support & Resistance Levels
Support Level
$7.73
Resistance Level
$10.07
Current Trend
Strong Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.30
Wall Street Target
$21.40
(+159.4%)
Revenue Growth (YoY)
1706.4%
Profit Margin
-260.9%
PE vs Historical
-6.3 vs 18.0
CHEAP
Share & Embed Analysis
Last updated: June 15, 2026 4:47 AM ET
Data refreshes hourly during market hours. Next update: 5:47 AM
Data refreshes hourly during market hours. Next update: 5:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
Advanced PRTA Option Strategies
Professional options setups generated by AI based on today's PRTA price and gamma walls.
